PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. [electronic resource]
Producer: 20201105Description: 5692 p. digitalISSN:- 2045-2322
- Animals
- Antineoplastic Agents -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- ErbB Receptors -- genetics
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mutation
- Piperazines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Receptor, ErbB-2 -- genetics
- Receptor, ErbB-4 -- genetics
- Signal Transduction
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.